Clinical Research Directory
Browse clinical research sites, groups, and studies.
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Sponsor: Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Summary
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Official title: Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-Aβ mAb CED Study)
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
8680
Start Date
2023-07-06
Completion Date
2029-06-30
Last Updated
2023-09-28
Healthy Volunteers
No
Interventions
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
Locations (1)
Centers for Medicare and Medicaid Services
Baltimore, Maryland, United States